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ABSTRACT
Inhibition of the constitutively activated JAK/STAT pathway in JAK2V617F 
mutated cells by the JAK1/JAK2 inhibitor ruxolitinib resulted in clinical benefits in 
patients with myeloproliferative neoplasms. However, evidence of disease-modifying 
effects remains scanty; furthermore, some patients do not respond adequately to 
ruxolitinib, or have transient responses, thus novel treatment strategies are needed. 
Here we demonstrate that ruxolitinib causes incomplete inhibition of STAT5 in 
JAK2V617F mutated cells due to persistence of phosphorylated serine residues of 
STAT5b, that conversely are targeted by PI3K and mTORC1 inhibitors. We found that 
PI3K/mTOR-dependent phosphorylation of STAT5b serine residues involves Protein 
Phosphatase 2A and its repressor CIP2A. The levels of CIP2A were found increased 
in cells harboring the JAK2V617F mutation, and we provide evidence of a correlation 
between clinical responses and the extent of CIP2A downregulation in myelofibrosis 
patients receiving the mTOR inhibitor RAD001 in a phase II clinical trial. To achieve 
maximal inhibition of STAT5 phosphorylation, we combined ruxolitinib with BKM120, 
a PI3K inhibitor, and RAD001, an mTOR inhibitor, obtaining improved efficacy in 
JAK2V617F mutated cell lines, primary patients’ cells, and JAK2V617F knock-in mice. 
These findings contribute to understanding the effectiveness of PI3K/mTOR inhibitors 
in MPN and argue for the rationale to develop combination clinical trials. 
INTRODUCTION
Clonal proliferation of hematopoietic progenitor 
cells and dysregulated production of blood cells of 
different lineages are the main characteristics of chronic 
myeloproliferative neoplasms (MPN) [1]. MPN include 
Essential Thrombocythemia (ET), Polycythemia Vera 
(PV) and Primary Myelofibrosis (PMF). Following the 
description of the JAK2V617F mutation [2, 3], additional 
somatic driver mutations were discovered in JAK2 wild-
type patients, including JAK2 exon12 mutations in PV [4] 
and thrombopoietin receptor (MPL) [5, 6] and calreticulin 
(CALR) mutations in ET and PMF [7, 8]. Additional myeloid-
malignancies associated mutations involving epigenetic or 
spliceasome genes were described in 5% to 40% of MPN 
patients, and serve as prognostic variables [9, 10].
The JAK1 and JAK2 inhibitor ruxolitinib [11] 
is approved for patients with myelofibrosis [12] and 
with PV [13, 14] resistant or intolerant to hydroxyurea. 
However, ruxolitinib, as well as other JAK2 inhibitors 
under development, is not selective for the mutated JAK2 
and inhibits the JAK/STAT signaling also in JAK2 wild-
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type cells. Although ruxolitinib reduces to some extent the 
mutated allele burden after long-term treatment, only few 
patients eventually achieve complete molecular response 
[15]. The lack of a clear disease-modifying effect of 
ruxolitinib [16, 17] might be ascribed to an underlying 
mutation complexity of clonal hematopoietic progenitors 
and/or to hyperactivated signaling pathways other than 
JAK/STAT, including in particular the PI3K/mTOR 
cascade [18–21]. 
In normal cells, PI3K-dependent signals contribute 
to the regulation of cell survival and proliferation through 
the activation of downstream kinases such as Akt and 
the mammalian target of rapamycin, mTOR; the latter is 
found in the different complexes, mTORC1 and mTORC2, 
and in turn controls downstream effectors including the 
transcription factor 4e binding protein 1 (4eBP1) and 
p70 s6 kinase (p70s6K). In normal hematopoiesis, the 
PI3K/mTOR pathway is essential for erythroid and 
megakaryocytic differentiation [22]. The different key 
kinases of the PI3K/Akt pathway were found deregulated 
or hyperactivated [23] in solid and hematologic 
malignancies [24, 25]. This pathway is deregulated also in 
cells expressing the JAK2V617F mutation [3], particularly 
in megakaryocytes of MPN patients [26]. 
Evidences favoring the relevance of targeting PI3K/
mTOR pathway in MPN derive from cellular and animal 
models [27, 28]; furthermore, in a phase I/II clinical trial 
in patients with myelofibrosis, the mTORC1 inhibitor 
RAD001 (Everolimus) demonstrated clinical effectiveness 
by reducing splenomegaly and improving constitutional 
symptoms [29]. Other studies demonstrated an added 
efficacy by combining inhibitors of the PI3K/mTOR and 
JAK/STAT pathway [30, 31]. However, the molecular 
basis of the functional crosstalk between the JAK/STAT 
and PI3K/mTOR pathway in JAK2V617F mutated cells 
remained poorly characterized. In this work, we show 
that signals originated by the activated JAK2 and PI3K 
pathway in JAK2V617F mutated cells specifically control 
the phosphorylation of different residues of STAT5. This 
might contribute to explain the persistence of activated 
STAT5 in cells exposed to JAK1/2 inhibitor ruxolitinib 
alone as well as the synergism exerted by combination 
of ruxolitinib with PI3K and mTOR inhibitors. Overall, 
these data provide mechanistic explanation for the 
involvement of PI3K/mTOR signaling in cells harboring 
the JAK2V617F mutation and might be translationally 
relevant for designing innovative strategies in MPN.
RESULTS
STAT5 is differentially phosphorylated by 
activated JAK2 and PI3K/mTOR pathway in 
JAK2V617F mutated cells
We previously reported that STAT5 phosphorylation 
in JAK2V617F mutated cells was down-regulated after 
exposure to drugs targeting the PI3K/mTOR signaling 
[27, 31]. In order to clarify the mechanism(s) by which 
inhibition of PI3K/mTOR signaling prevented STAT5 
phosphorylation, we comparatively examined the 
pattern of phosphorylated STAT5a and STAT5b residues 
following treatment of the cells with the JAK1/2 inhibitor 
ruxolitinib, different PI3K/mTOR inhibitors (mTORC1 
inhibitor RAD001, mTORC1/2 inhibitor PP242, and PI3K/
mTORC1/2 inhibitor BEZ235) and the pan PI3K inhibitor 
BKM120 (Figure 1A). As expected, using JAK2V617F 
mutated SET2 cells, we found that ruxolitinib dose-
dependently reduced phosphorylated STAT5 Tyrosine-694 
(Y694) that, together with Tyrosine-699 (not shown), is 
the immediate target of activated JAK2 in human STAT5a 
and STAT5b, respectively. Conversely, none of the PI3K 
and/or mTOR inhibitors tested were able to affect the 
phosphorylation of Y694. However, all the PI3K/mTOR 
inhibitors caused a dose-dependent reduction of the 
phosphorylation of Serine-731 (S731) and Serine-193 
(S193) residues of STAT5b; of note, these serine residues 
on STAT5b were not affected by exposure to ruxolitinib. 
Since RAD001, an mTORC1 complex inhibitor, reduced 
phosphorylation of S731 and S193 at levels comparable 
to those obtained with BEZ235 and BKM120, that are 
PI3K inhibitors, we interpreted these findings as indicating 
that phosphorylation of serine residues of STAT5b is a 
RAD001 sensitive, mTORC1-dependent phenomenon. 
To support the hypothesis, we performed siRNA-
mediated mTOR silencing in SET2 cells (Figure 1B). The 
expression levels of mTOR and its target phospho-4eBP1 
were almost completely abolished at 24 hours following 
siRNA transfection, confirming effective silencing, and 
were accompanied by marked reduction of phosphorylated 
S731 and S193 residues of STAT5b, thereby excluding 
off-target effects of PI3K/mTOR inhibitors. Conversely, 
the levels of phosphorylated Y694 in STAT5a did not 
change appreciably after siRNAs treatment. Finally, we 
assessed the phosphorylated status of STAT5 tyrosine 
and serine residues in peripheral blood granulocytes 
of JAK2V617F mutated MPN patients using confocal 
microscopy (Figure 2). We found that phosphorylated 
Y694 as well as S193 and S731 residues were clearly 
marked in patients’ cells as compared to control cells. 
Overall, these findings indicate that in cells expressing the 
JAK2V617F mutation, STAT5 is phosphorylated on both 
tyrosine and serine residues as the result of JAK2- and 
PI3K/mTOR-dependent mechanisms, respectively. 
STAT5 de-phosphorylation induced by PI3K/
mTOR inhibitors is mediated by Phosphatase-2a 
and its inhibitor CIP2A
To address the mechanism(s) underlying STAT5 
serine de-phosphorylation induced by PI3K/mTOR 
inhibitors in JAK2V617F mutated cells, we focused 
on protein phosphatases, that are the enzymes mainly 
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responsible of protein de-phosphorylation [32–34], 
and their inhibitors. Owing that about 90% of cell 
phosphatases are constituted by phosphatase 1 (PP1) and 
2 (PP2A) [35], we first used the chemical phosphatases 
inhibitor Calyculin A (CA). We found that CA exposure 
caused, respectively, a 1.3±0.2 and 2.1±0.4 fold increase 
of phosphorylated S731 and S193 residues of STAT5b 
(P < 0.05 for both versus untreated cells, mean±SD of 4 
experiments), and also prevented their de-phosphorylation 
when BKM120 was added to the cells (Figure 3A). 
Notably, CA treatment did not affect the levels of phospho 
Y694. As expected by the mechanism of action of CA, 
the levels of PP1 and PP2A protein remained unchanged 
(Figure 3A). To assess the contribution of the different 
phosphatases, we silenced individually PP1 or PP2A with 
specific siRNAs before treating the cells with BKM120. 
Only PP2A silencing was capable to effectively prevent 
the BKM120-induced de-phosphorylation of S731 and 
S193, while down-regulation of PP1 had no effects on 
serine phosphorylation levels (Figure 3B). These changes 
could be reproduced in multiple experiments (n = 5) even 
though we succeeded in inducing only a 50–60% down-
regulation of phosphatase expression levels (in spite of 
different sets of siRNAs employed, not shown in detail). 
Taken together, these data illustrate a prominent role of 
PP2A in the de-phosphorylation of STAT5b serine residues 
induced by BKM120, and indirectly support a defective 
PP2A activity in cells harboring the JAK2V617F mutation. 
The activity of PP2A in the cells is mainly regulated 
by CIP2A (Cancerous Inhibitor of PP2A) and I2PP2a 
(Inhibitor 2 of Protein Phosphatase 2A) (also named 
SET) [36] through allosteric inhibition of phosphatase. 
We reasoned that reduced activity of PP2A, eventually 
leading to increased phosphorylation of STAT5 serine 
residues in JAK2V617F mutated cells, might result from 
excessive inhibition exerted by endogenous inhibitors. 
Therefore, we treated SET2 cells with different PI3K 
and mTOR inhibitors and with ruxolitinib and measured 
the levels of CIP2A and I2PP2A mRNA. Ruxolitinib did 
not change the baseline levels of CIP2A mRNA while 
PI3K inhibitor BKM120 and the double PI3K and mTOR 
inhibitor BEZ235 dramatically reduced CIP2A mRNA 
and protein levels (Figure 4A). The mTORC1 inhibitor 
Everolimus and the double mTORC1/2 inhibitor PP242 
caused less impressive, yet statistically significant, 
down-regulation of CIP2A levels (Figure 4A). Of note, 
the extent of CIP2A down-regulation and the levels of 
phospho-4eBP1, the direct target of PI3K/mTOR, were 
congruent (Figure 4A). On the contrary, we found no 
appreciable change of I2PP2a mRNA levels with any of 
the inhibitors tested (Supplementary Figure 1), confirming 
the specific involvement of CIP2A in controlling PP2A 
activity in JAK2V617F mutated cells. Furthermore, we 
showed that siRNA-mediated inhibition of CIP2A mRNA 
resulted in marked de-phosphorylation of serines 731 and 
193 of STAT5b, but not tyrosine 694; levels of STAT5a 
and b, PP1 and PP2A were unchanged (Figure 4B). 
It was reported that the tumor suppressor miR-375 
represses CIP2A mRNA through multiple miRNA-
mRNA interactions [37, 38], and it is in turn negatively 
regulated by SNAI1 (Snail) [39, 40]. Therefore, we 
wanted to ascertain whether the reduction of CIP2A levels 
determined by PI3K/mTOR inhibitors involved miR-375. 
We found that when BKM120 was added to SET2 and 
HEL cells, the levels of miR-375 increased markedly, 
and such an increase was associated with concurrently 
decrement of CIP2A and Snail. On the contrary, ruxolitinib 
did not affect Snail, miR-375 and CIP2A expression, 
Figure 1: PI3K/mTOR inhibitors modulate phosphorylation pattern of STAT5. (A) pattern of phosphorylation of tyrosine and 
serine residues on STAT5a and STAT5b, respectively, and the effects of the JAK1 and JAK2 inhibitor ruxolitinib and of different inhibitors 
of the PI3K/mTOR pathway. BKM120 is a PI3K inhibitor, BEZ235 is a dual PI3K/mTOR inhibitor, RAD001 and PP242 are inhibitors 
of mTORC1 and mTORC1/2, respectively.  SET2 cells were exposed for 24 h to increasing concentrations of the drugs and cell extracts 
were processed by western blotting analysis with indicated antibodies. A representative experiment of at least four. (B) Effects of mTOR 
silencing by specific siRNA on the levels of phosphorylated tyrosine and serine residues of STAT5a/b in SET2 cells. The mTORC1 target 
phospho-4eBP1 was used as a control of functional inhibition of mTORC1 signaling. Tubulin was used as loading control. Densitometric 
analysis was performed using ImageJ software. Data are from one representative experiment out of three.
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therefore addressing specifically these effects to the PI3K/
mTOR pathway (Figure 4C). 
To clarify a possible role of CIP2A in the 
constitutive phosphorylation of serine residues of STAT5 
in primary JAK2V617F mutated cells, we measured 
CIP2A mRNA levels in granulocytes of MPN patients 
(3 PV, 9 MF) and healthy controls (n = 15) (Figure 4D). 
We found that the levels of CIP2A mRNA were 3.28-
fold higher (±1.2) in patients’ granulocytes compared to 
donors’ cells (P < 0.05), further supporting abnormally 
Figure 2: Autonomous phosphorylation of STAT5 residues Y694, S193 and S731 in untouched granulocytes from a 
JAK2V617F mutated patients with myelofibrosis, analyzed by confocal microscopy. Control cells from a healthy donor are shown 
on the right. Cells were isolated by density gradient and probed with phospho-specific anti-STAT5 antibodies. Topro-3 was used as nucleus 
marker. Microscopic images were taken by a LSM 510 META Zeiss confocal microscope system, using 40X oil immersion lens, corresponding 
to a 400X magnification. For images analysis Zeiss Confocor 2 software was used. A representative experiment out of 5 is shown.
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increased CIP2A levels as a mechanism for reduced PP2A 
activity in patients’ cells. The relevance of this observation 
was strengthened by the analysis of CIP2A mRNA levels 
in granulocytes from 14 patients with myelofibrosis who 
had received RAD001 in a phase II clinical trial [29]. The 
CIP2A mRNA levels were measured after 3 (±2) months 
of treatment and, after being normalized to pre-treatment 
levels, were correlated with clinical outcome according 
to the IWG-MRT criteria [41]. Interestingly, we observed 
that all 7 patients who had a clinical response to treatment 
(defined as reduction of splenomegaly and symptomatic 
improvement) showed overt down-regulation of CIP2A 
mRNA levels, ranging from -40% to -99.6% the baseline 
levels, while all the 7 patients who did not benefit from 
treatment (non responders) showed no changes or even 
an increase of CIP2A mRNA levels (Figure 4E). As a 
whole, results from these experiments point to exaggerated 
increase of CIP2A levels in JAK2V617F mutated cells as 
the main reason for defective PP2A activity, that might 
be responsible for deregulated STAT5b serine residues 
phosphorylation, and mechanistically associate such an 
increase with abnormal signaling originated by the PI3K/
mTOR pathway. 
Concurrent inhibition of STAT5 phosphorylated 
tyrosine and serine residues produces synergism 
against JAK2V617F mutated cells 
The findings of persistent STAT5b serine residues 
phosphorylation in JAK2V617F mutated cells exposed 
to ruxolitinib indicate incomplete inhibition of phospho-
STAT5-mediated signaling. Tyrosine phosphorylation 
allows STAT5 to dissociate from the receptor complex 
and promotes the formation of hetero- or homodimers 
and their translocation to the nucleus to activate target 
genes transcription [42]. On the other hand, the phospho-
serine sites located in a conserved Pro-Ser-Pro motif in 
the transactivation domain are required for maximum 
transcriptional activity of STAT5 [43, 44]. Therefore, 
we wanted to explore the hypothesis that complete de-
phosphorylation of STAT5, involving also the serine 
residues in addition to the tyrosines that are inhibited by 
ruxolitinib, might result in more pronounced inhibition 
of JAK2V617F mutated cells. For these studies we 
used as relevant drugs the pan PI3K inhibitor BKM120, 
that is being tested in a clinical trial in association with 
ruxolitinib [45], and the mTORC1 complex inhibitor 
RAD001, that was already employed as single agent in 
myelofibrosis [29], and has been characterized in in-vitro 
models [27].
In a preliminary set of experiments, we evaluated 
the efficacy of BKM120 as single agent in in-vitro models 
of JAK2V617F mutated cells, by measuring changes in 
cell proliferation, cell cycle and  apoptosis (Supplementary 
Figure 2), and by determining colony formation in cultures 
established with MPN hematopoietic progenitor cells 
(Supplementary Table 1 and Supplementary Figure 3); 
we also analyzed the effects of BKM120 on survival of 
mice injected with Ba/F3 JAK2V617F-Luc+ cells [31] 
(Supplementary Figure 4). Results from these experiments, 
that are detailed in the respective Figure legends, 
indicated that BMK120 was able to effectively inhibit 
the proliferation, and induce apoptosis, of JAK2V617F 
mutated mouse and human cell lines, potently inhibit the 
growth of erythropoietin-independent erythroid colonies 
from MPN patients, and reduce the dissemination of Ba/
F3 JAK2V617F-Luc+ mutated cells in mice prolonging 
their survival.
Figure 3: PP2A is involved in the de-phosphorylation of STAT5 serine residues in JAK2V617F mutated cells. (A) SET2 
cells were pre-treated for 2 hours with the chemical phosphatase inhibitor Calyculin A  (CA; 10 nM) before the addition of 5μM BKM120 
for 24 hours. CA exposure resulted in  increased phosphorylation of STAT5b serine residues and prevented their BKM120-induced de-
phosphorylation, as opposite to STAT5a Y694 residue that remained unchanged. (B) Specific siRNAs were used to silence, although only 
partially, either PP1 or PP2A to dissect their unique role in the BKM120-induced de-phosphorylation of S731 and S193 of STAT5b. Tubulin 
was used as loading control. One of 5 different experiments is shown. Densitometric analysis was performed using ImageJ software.
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Figure 4: The expression of the PP2A inhibitor CIP2A affects the phosphorylation pattern of STAT5 serine residues. 
(A) PI3K/mTOR inhibitors treatment of SET2 cells for 24 h induces a various degree of CIP2A mRNA downregulation (ranging from -20% 
to –80% vs control) as assessed by qRT-PCR (on the left) and western blotting (on the right) analysis. (B) CIP2A was silenced by specific 
siRNA, and the effects on the phosphorylation status of STAT5 S731, S193 and Y694 residues were monitored. (C) The levels of miR-375 
and CIP2A and SNAI1 mRNAs were monitored by qRT-PCR in SET2 and HEL cells that had been exposed to BKM120 or ruxolitinib. 
(D) CIP2A mRNA levels were quantified by qRT-PCR in granulocytes isolated from the peripheral blood of 12 JAK2V617F mutated MPN 
patients and 15 healthy controls. (E) Correlation of changes of CIP2A mRNA levels with clinical response to treatment in 14 patients 
with myelofibrosis who had been enrolled in a phase II trial with the mTOR1 inhibitor RAD001 (everolimus). A qRT-PCR analysis was 
performed in peripheral blood samples collected after 3 months of treatment. All P values were determined by unpaired two-tailed Student’s 
T test and confirmed by BootstRatio test on fold change data (*P < 0.05, **P < 0.01).
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Based on the above findings indicating activity of 
BKM120 as single agent in different MPN models, we 
went to combine ruxolitinib with BKM120 and RAD001. 
We first assessed the combination index (C.I.), to ascertain 
possible synergistic activity of drugs combination. The 
IC
50
 values were significantly lower when BKM120, 
ruxolitinib and RAD001 were combined compared 
to individual drugs, in cultures of Ba/F3 JAK2V617F 
(P < 0.05) and SET2 cells (P < 0.05) (Supplementary 
Table 2), indicating high synergism of triple treatment. 
In particular, the C.I. of triple combination of BKM120, 
ruxolitinib and RAD001 in SET2 was significantly 
lower (P < 0.05) than for the combination of BKM120 
and ruxolitinib only. Furthermore, the combination of 
suboptimal doses of BKM120, RAD001 and ruxolitinib 
led to a stronger inhibition of the phosphorylation of 
tyrosine and serine residues of STAT5a and b in SET2 
cells than that obtained with single drugs (Figure 5A). 
In order to document the downstream transcriptional 
consequences of reduced STAT5 activity caused by the 
inhibitors, we assessed the expression levels of Bcl-2, a 
well characterized STAT5 target gene [46], in SET2 cells 
exposed to single agents and triple combination. As shown 
in Figure 5B, Bcl-2 mRNA levels were significantly 
reduced by any of the drugs tested (up to a mean of 
18%, 65% and 43% the baseline levels, respectively for 
RAD001, ruxolitinib and BKM120), while the triple 
combination resulted in an almost complete inhibition 
of gene expression (<5% the baseline levels). The triple 
drug combination was further assessed in clonogenic assay 
of hematopoietic progenitors of JAK2V617F mutated 
patients, plated in semisolid medium in presence of each 
single drug and two different doses of triple combination 
(Figure 5C). The colonies generated in presence of the 
most effective triple drug combination (ruxolitinib 50 
nM, BKM120 150 nM, RAD001 150 nM) decreased by 
62.6% compared to control cultures (P < 0.006), and by 
33.0%, 29.3% and 27.3%, respectively, in the presence of 
RAD001 (P < 0.04), BKM120 and ruxolitinib (P < 0.05) 
as single drugs. Finally, to assess the ability of treatment 
to preferentially target JAK2V617F mutated cells, we 
plated BM cells obtained from JAK2V617F knock-in and 
wild-type mice [47], in a 1:1 ratio, in the presence of triple 
drug combination; individual colonies were harvested and 
genotyped. We found that triple treatment reduced the 
proportion of JAK2V617F-positive colonies from 50% at 
baseline to 18% on day 4 (P < 0.05) (Figure 5D). 
Concurrent JAK2 and PI3K and mTOR 
inhibition is highly effective in JAK2V617F 
knock-in mice
We then used JAK2V617F knock-in mice to test 
the effects of treatment with the triple combination of 
BKM120, RAD001 and ruxolitinib; these mice develop 
a progressive myeloproliferative disease starting from 
the first months after birth, characterized by marked 
erythrocytosis, thrombocytosis and leukocytosis, 
and splenomegaly, that mimics PV and evolves to 
myelofibrosis at later stages [47]. Mice were treated 
daily for 16 days with 3 mg/kg body weight (mpk) 
RAD001, 60 mpk ruxolitinib or 60 mpk BKM120, and 
with the combination of the three drugs at half the dose 
used as single agent. Treatment was well tolerated and 
the body weight loss was <10% in all treatment groups; 
histopathology of the liver revealed the absence of overt 
hepatotoxicity (Supplementary Figure 5). Triple drug 
combination induced a dramatic reduction of splenomegaly 
(Figure 6A), macroscopically much more evident than in 
animals treated with single agents. The median spleen 
index of triple treated cohort was 1.1 compared with 3.6 
in control vehicle-treated mice (P < 0.01), 2, 2.3 and 3.4 
respectively for BKM120, ruxolitinib (both P < 0.05) 
and RAD001 (P < 0.01). Histopathology showed a 
marked reduction of megakaryocytes and myeloid cells 
infiltrating the BM and the spleen in mice treated with the 
triple drug combination; in the spleen, the overall tissue 
architecture was improved towards normal appearance 
with splenic lymphoid follicles being restored (Figure 6B). 
Conversely, in mice receiving single drugs, including 
ruxolitinib, changes of BM and spleen cellularity and 
architecture were barely detected. The mean reticulocyte 
count per HPF in mice receiving drug combination was 
11 compared to 48 in vehicle mice (P < 0.01), 50, 29 and 
33 in mice receiving RAD001 (P < 0.01), ruxolitinib or 
BKM120 (P < 0.05), respectively (Figure 6C). Although 
not statistically significant, there was a trend towards 
reduced leukocyte and platelet counts in mice receiving 
the triple combination compared with the vehicle group 
(Figure 6D).
DISCUSSION
Preventing and reducing STAT5 activation through 
the use of JAK2 inhibitors proved clinical efficacy in 
patients with myelofibrosis and PV [48, 49], and the 
first-in-class JAK1 and JAK2 inhibitor ruxolitinib was 
approved recently for selected categories of patients. In 
fact, constitutive activation of the JAK/STAT signaling 
pathway is considered the basic pathogenic mechanism 
of MPN, through either direct, as in patients harboring 
mutations of JAK2, or indirect, as for MPL or CALR 
mutations, involvement of JAK2, that in turn leads to 
sustained phosphorylation of STAT5. Complete deletion of 
STAT5a/b in JAK2V617F mice prevented the development 
of PV, thereby supporting the relevance of STAT5a/b as 
target for therapy [50]. However, in spite of the impressive 
clinical benefits in patients receiving ruxolitinib, it is 
still debated if the drug has the potential to modify the 
course of disease; in fact, the JAK2 mutant variant allele 
frequency reduced appreciably in a proportion only of 
the patients, and complete molecular remissions were 
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Figure 5: Effects of combining BKM120, RAD001 and ruxolitinib (triple drug combination) in different MPN models. 
(A) SET2 cells were exposed to suboptimal amounts of BKM120, RAD001 and ruxolitinib as single drugs (see Figure 1 for comparison), 
or in combination, and the effects on the phosphorylation of S731, S193 and Y694 of STAT5 and of 4eBP1, and the levels of CIP2A, were 
assessed by western blotting. (B) The mRNA amount of the STAT5 target gene Bcl-2 was assessed in SET2 cells treated with single drugs or 
drug combination by qRT-PCR. (C) Bone marrow mononuclear cells isolated from 6 JAK2V617F patients were plated in semisolid medium 
in presence of single agents or in combinations at two different dose levels. Colony formation was expressed as percent of the number of 
colonies enumerated in control dishes (no drug). (D) Bone marrow cells of JAK2V617F KI and wild type mice were mixed in a 1:1 ratio 
and plated in semisolid medium in the presence of BKM120 plus RAD001 and ruxolitinib, 30 nM each. Individual colonies harvested at day 
4 of culture (to avoid colonies overlapping) were genotyped by allele specific PCR. All P values were determined by unpaired two-tailed 
Student’s T test and confirmed by BootstRatio test on fold change data (*P < 0.05, **P < 0.01).
Oncotarget96718www.impactjournals.com/oncotarget
Figure 6: Efficacy of BKM120, RAD001 and ruxolitinib, single or in triple combination, in JAK2V617F knock-in mice. 
Animals received treatment for 16 days before sacrifice; control mice received vehicle only with the same schedule as treated ones. 10 mice 
for each treatment cohort were analyzed. (A) Effects of triple treatment on spleen size (upper panel) and spleen index (calculated as ratio of 
spleen and body weight x100) compared to other treatment groups and controls. (B) Histopathology of the spleen and bone marrow in control 
and treated mice. Picture were taken with a LEICA DM LS2 microscope using a N-Plan × 20 objective. (C) The number of reticulocytes 
per 10 high power fields in peripheral blood smears. (D) The number of white blood cells and platelets in the peripheral blood of mice 
treated with drugs combination; values in mice receiving each single drug were comparable to controls and are not shown. All P values were 
determined by unpaired two-tailed Student’s T test and confirmed by BootstRatio test on fold change data (*P < 0.05, **P < 0.01).
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rare [51]; similarly, resolution of abnormal bone marrow 
histopathology was reported only occasionally, although 
stabilization was noted in several patients after 2–3 
years of treatment [52]. One possible explanation for the 
partial efficacy of ruxolitinib is the persistence of STAT5 
activation mediated by JAK2-dependent and/or JAK2-
independent mechanisms. In previous studies, we [27, 31] 
and others [53, 54] showed that phosphorylation of STAT5 
in cells harboring the JAK2V617F mutation is mediated 
by activated PI3K/mTOR, and could be reduced by target 
PI3K/mTOR inhibitors. However, the mechanistic basis 
of these observations, as well as the ultimate relevance 
for designing novel treatment strategies, remained largely 
unknown.
In this work we present evidence that MPN 
cells exposed to ruxolitinib, that effectively reduced 
phosphorylation of the key Y694 tyrosine residue of 
STAT5a, demonstrated persistence of phosphorylation at 
the serine residues of STAT5b; we also show that these 
residues are under the control of the PI3K/mTOR signaling 
and resulted specifically targeted by inhibitors acting at 
different levels of the pathway. We also demonstrated that 
the deregulated serine phosphorylation of STAT5b may be 
due to the defective activity of the protein phosphatase 2A 
as the consequence of increased inhibition exerted by the 
allosteric inhibitor CIP2A; furthermore, it is shown here 
for the first time, to the best of our knowledge, that CIP2A 
is over-expressed in MPN patients compared to healthy 
controls. The fact that CIP2A resulted down-regulated in 
cells exposed to different PI3K-pathway inhibitors, but not 
ruxolitinib, specifically linked the deregulation of PP2A/
CIP2A to the PI3K/mTOR signaling in JAK2V617F 
mutated cells. Therefore, by relieving CIP2A inhibition 
of PP2A, the PI3K inhibitors would enforce PP2A action 
in de-phosphorylating target residues on STAT5 thereby 
resulting in reduced activation. The changes in CIP2A 
levels in cells exposed to PI3K/mTOR inhibitors were 
under the control of a microcircuit involving Hif1α [55, 
56] and its target SNAI1 [57], and caused enhanced 
expression of miR-375, a known negative regulator of 
CIP2A transcription. A schematic representation of this 
pathway, on the basis of information derived from the 
literature and original data from this work, is illustrated 
in Figure 7.
These findings provide an explanation for the 
reported efficacy of PI3K/mTOR inhibitors in different 
models of MPN, as well as for the clinical efficacy of 
the mTOR inhibitor RAD001 in myelofibrosis, and 
offer a rationale for combination therapy. In fact, in 
our experiments, the concurrent blockade of JAK2 and 
PI3K/mTOR pathway signaling produced synergistic 
inhibition of STAT5 phosphorylation, resulting in effective 
prevention of cell proliferation in-vitro and improved 
control of myeloproliferation in JAK2V617F knock-in 
mice. We showed that inhibition of PI3K/mTOR pathway 
was best achieved by concurrent exposure to BKM120 
(a PI3K inhibitor) and RAD001 (a mTOR inhibitor), 
that when used together might prevent the well known 
rebound activation of AKT by mTOR inhibitors alone. The 
relevance of these data for the clinics is that both drugs 
are already being used in clinical trials, and they might be 
combined as well as with low doses of ruxolitinib. Finally, 
our findings also suggest that PP2A may serve as a novel 
therapeutic target for modulating the extent of STAT5 
activation in MPN.
MATERIALS AND METHODS
Compounds and reagents 
BKM120 (a selective pan class-I PI3-Kinase 
inhibitor), RAD001 (a mTOR specific allosteric inhibitor 
active against TORC1), BEZ235 (a double PI3K and 
mTOR inhibitor) and  ruxolitinib (a JAK1/JAK2 kinase 
inhibitor) were kindly provided by Novartis (Basel, 
Switzerland); PP242 was purchased from Sigma-Aldrich 
(St Louis, MO, US). In-vitro and in-vivo formulations and 
administration schedules are detailed in Supplementary 
Methods.
Cell Lines 
The following human: HEL (JAK2V617F mutated), 
K562 (BCR/Abl positive), SET2 (JAK2V617F mutated); 
and murine: Ba/F3 and Ba/F3-EPOR cells expressing 
JAK2 wild-type (wt) or JAK2V617F (VF) cell lines 
were used, as previously described [27] and detailed in 
Supplementary Methods. 
Human and murine cells and colony assay
Peripheral blood (PB) samples were obtained from 
PV or PMF patients, diagnosed according to the 2008 
WHO criteria, under a protocol approved by Institutional 
Review Board of Azienda Ospedaliera-Universitaria 
Careggi and after obtaining a written informed consent. 
Mononuclear cells (MNCs) and Granulocytes from 
MPN patients or control subjects were isolated by Ficoll 
Hipaque (Lonza). MNCs were plated at 1×105/mL in 
methylcellulose supplemented with stimulating factors 
(detailed in Supplementary Methods) and enumerated on 
day 14 according to standard criteria. For murine colony 
assay, BM cells were harvested from JAK2 wild-type and 
V617F mice and plated in a 1:1 ratio in presence of drugs. 
Single colonies were harvested on day 4 and submitted 
to conventional PCR in order to discriminate the JAK2 
mutational status. 
Confocal microscopy
Granulocytes were isolated from JAK2V617F 
MPN patients. Fixed and permeabilized cells were 
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incubated with relevant primary antibodies followed by 
anti-rabbit IgG Alexa Fluor-488 conjugated. Microscopic 
images were taken by a LSM 510 META Zeiss confocal 
microscope system (Carl Zeiss Inc., Jena, Germany) 
and analyzed by Confocor 2 (Zeiss) software (details in 
Supplementary Methods).
siRNA transfection
Gene silencing was performed by siRNAs 
transfection according to Nucleofector technology 
(Lonza): mTOR, PP1, PP2A, CIP2A and non-targeting 
control siRNAs were from Cell Signaling Technologies 
(Danvers, MA, US). 
Cell lysis and SDS-PAGE western blotting 
Cells were lysed in RIPA lysis buffer containing 
a proteinase inhibitor cocktail and assayed in western 
blotting analysis, as described in Supplementary 
Methods. Images were acquired with ChemiDoc XRS+ 
(Bio-Rad, Hercules, CA, US) and analyzed with ImageJ 
software [58] for densitometric analysis. In all cases, a 
representative experiment of three is shown.  
RNA isolation and quantitative real-time PCR 
(qRT-PCR)
Total RNA was extracted and reverse-transcribed 
to cDNA, then subjected to quantitative real-time PCR 
(qRT-PCR) according to standard protocols. Methods and 
primers for qRT-PCR analysis are listed in Supplementary 
Methods. Relative gene expression was calculated 
according to the comparative cycle threshold (Ct) and 
2-DDCt method.
JAK2V617F KI mouse model
All animal procedures were performed according to 
Italian laws in an animal facility (Ce.S.A.L., University 
Figure 7: Schematic representation of the role of PI3K/mTOR signaling and PP2A/CIP2A axis in the phosphorylation 
of STAT5b in JAK2V617F mutated cells. On the left part of the figure, the activated JAK2-dependent tyrosine phosphorylation 
of STAT5a is also depicted. Constitutive signaling by JAK2V617F promotes phosphorylation of STAT5 at the key Y694 residues; 
activated STAT5 monomers dimerize and translocate to the nucleus functioning as transcription factor for target genes. Ruxolitinib causes 
de-phosphorylation of Y694 on STAT5a, but leaves untouched the S731 and S193 residues of STAT5b that are essential for full activity of 
STAT5. STAT5b serine residues are targeted by PI3K/mTOR inhibitors. Cells with the JAK2V617F mutation express abnormally increased 
levels of the phosphatase 2A (PP2A) inhibitor CIP2A, that resulted down-regulated by PI3K/mTOR inhibitors via a microcircuit that 
includes SNAI1 and miR375. The JAK2/PI3K-pathway cross-talk described in this work, converging on unique phosphorylation targets on 
STAT5, contributes to the understanding of the pathophysiology of MPN and offers the rationale for combination therapies centered on a 
more effective inhibition of activated STAT5. 
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of Florence) under humanized conditions. KI mice were 
generated and experimental procedures were carried out 
as described [31]. Three months-aged KI mice received 
the drugs for indicated periods administered by oral 
gavage and were euthanized by CO2 inhalation. Blood 
parameters were measured using the Sysmex XE5000 
(Sysmex, Hyogo, Japan) cell counter, while reticulocytes 
were counted in methylene blue-stained blood smears. 
The spleen was collected and weighted; to accomplish for 
variations in body weight at baseline, a spleen index (i.e., 
spleen weight/body weight ×100) was calculated. 
Statistical methods
The level of significance from two-sided tests was 
P < 0.05. All P values were determined by unpaired two-
tailed Student’s T test and confirmed by BootstRatio test 
[59] on fold change data. The analysis of drug synergism 
was performed by calculation of the combination index 
(CI) according to the Chou and Talaly method [60] as 
reported in Supplementary Methods. 
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